News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients
This capability programme aims to upskill 5000 nurses across the country in the next year by converting the current modules into an e-learning one
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
This is the first time in South Asia an indigenously made drone was used to transport Covid-19 vaccines
The tracker gives week by week coverage of the first and second dose of vaccine and also their effectiveness
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
At present 18 per cent of the local pharmaceutical market is under government's price control
Subscribe To Our Newsletter & Stay Updated
